Overview

B-Cell Targeted Carfilzomib Desensitization

Status:
Recruiting

Trial end date:
2021-09-01

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to provide a preliminary evaluation of the safety and potential efficacy of carfilzomib in reducing HLA antibody levels in highly sensitized kidney transplant candidates.

Phase:

Phase 1

Details

Lead Sponsor:

E. Steve Woodle

Collaborators:

Amgen
Onyx Pharmaceuticals

Treatments:

Rituximab